Lipid-based drug delivery systems: Choosing the right in vitro tools

American Pharmaceutical Review

Volumn 10, Issue 3, 2007, Pages

  Müllertz, Anette ^a  

^a Faculty of Pharmaceutical Sciences   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG DELIVERY SYSTEM; DRUG FORMULATION; EMULSION; LIPID ABSORPTION; LIPOLYSIS; REVIEW;

EID: 55749107652     PISSN: 10998012     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (47)

1. Microemulsion: Structure and Dynamics. Friberg, S. E. and Botherel, P. 1987. CRC Press, Boca Raton, Florida. Ref Type: Serial (Book,Monograph)
2. Armand M, Pasquier B, Andre M, Borel P, Senft M, Peyrot J, Salducci J, Portugal H, Jaussan V and Lairon D. Digestion and absorption of 2 fat emulsions with different droplet sizes in the human digestive tract. American Journal of Clinical Nutrition 70: 1096-1106, 1999.
3. Aungst BJ. Intestinal permeation enhancers. Journal of Pharmaceutical Sciences 89: 429-442, 2000.
4. Benet LZ and Cummins CL. The drug efflux-metabolism alliance: biochemical aspects. Advanced Drug Delivery Reviews 50: S3-S11, 2001.
5. Borel P, Grolier P, Armand M, Partier A, Lafont H, Lairon D and Azais-Braesco V. Carotenoids in biological emulsions: solubility, surface-to-core distribution, and release from lipid droplets. J Lipid Res 37: 250-261, 1996.
6. Caliph SM, Charman WN and Porter CJH. Effect of short-, medium-, and long-chain fatty acid-based vehicles on the absolute oral bioavailability and intestinal lymphatic transport of halofantrine and assessment of mass balance in lymph-cannulated and non-cannulated rats. Journal of Pharmaceutical Sciences 89: 1073-1084, 2000.
7. Carriere F, Barrowman JA, Verger R and Laugier R. Secretion and Contribution to Lipolysis of Gastric and Pancreatic Lipases During A Test Meal in Humans. Gastroenterology 105: 876-888, 1993.
8. Charman SA, Charman WN, Rogge MC, Wilson TD, Dutko FJ and Pouton CW. Self-emulsifying drug delivery systems: formulation and biopharmaceutic evaluation of an investigational lipophilic compound. Pharm Res 9: 87-93, 1992.
9. Charman WNA and Stella VJ. Estimating the Maximal Potential for Intestinal Lymphatic Transport of Lipophilic Drug Molecules. International Journal of Pharmaceutics 34: 175-178, 1986.
10. Christensen JO, Schultz K, Mollgaard B, Kristensen HG and Mullertz A. Solubilisation of poorly water-soluble drugs during in vitro lipolysis of medium- and long-chain triacylglycerols. Eur J Pharm Sci 23: 287-296, 2004.
11. Christensen JO, Schultz K, Mollgaard B, Kristensen HG and Mullertz A. Solubilisation of poorly water-soluble drugs during in vitro lipolysis of medium- and long-chain triacylglycerols. Eur J Pharm Sci 23: 287-296, 2004.
12. Christensen KL, Pedersen GP and Kristensen HG. Physical stability of redispersible dry emulsions containing amorphous sucrose. Eur J Pharm Biopharm 53: 147-153, 2002.
13. Dollo G, Le CP, Guerin A, Chevanne F, Burgot JL and Leverge R. Spray-dried redispersible oil-in-water emulsion to improve oral bioavailability of poorly soluble drugs. Eur J Pharm Sci 19: 273- 280, 2003.
14. Dressman JB, Berardi RR, Dermentzoglou LC, Russell TL, Schmaltz SP, Barnett JL and Jarvenpaa KM. Upper Gastrointestinal (Gi) Ph in Young, Healthy-Men and Women. Pharmaceutical Research 7: 756-761, 1990.
15. Drewe J, Meier R, Vonderscher J, Kiss D, Posanski U, Kissel T and Gyr K. Enhancement of the oral absorption of cyclosporin in man. Br J Clin Pharmacol 34: 60-64, 1992.
16. Fatouros DG, Bergenstahl B and Mullertz A. Morphological observations on a lipid-based drug delivery system during in vitro digestion. Eur J Pharm Sci 31: 85-94, 2007.
17. Fatouros DG, Deen GR, Arleth L, Bergenstahl B, Nielsen FS, Pedersen JS and Mullertz A. Structural Development of Self Nano Emulsifying Drug Delivery Systems (SNEDDS) During In Vitro Lipid Digestion Monitored by Small-angle X-ray Scattering. Pharm Res 2007.
18. Gao ZG, Choi HG, Shin HJ, Park KM, Lim SJ, Hwang KJ and Kim CK. Physicochemical characterization and evaluation of a microemulsion system for oral delivery of cyclosporin A. International Journal of Pharmaceutics 161: 75-86, 1998.
19. Giller T, Buchwald P, Blumkaelin D and Hunziker W. 2 Novel Human Pancreatic Lipase Related Proteins, Hplrp1 and Hplrp2 - Differences in Colipase Dependence and in Lipase Activity. Journal of Biological Chemistry 267: 16509-16516, 1992.
20. Grove M, Pedersen GP, Nielsen JL and Mullertz A. Bioavailability of seocalcitol I: Relating solubility in biorelevant media with oral bioavailability in rats - effect of medium and long chain triglycerides. J Pharm Sci 94: 1830-1838, 2005.
21. Kalantzi L, Goumas K, Kalioras V, Abrahamsson B, Dressman JB and Reppas C. Characterization of the human upper gastrointestinal contents under conditions simulating bioavailability/bioequivalence studies. Pharmaceutical Research 23: 165-176, 2006.
22. Kaukonen AM, Boyd BJ, Porter CJH and Charman WN. Drug solubilization behavior during in vitro digestion of simple triglyceride lipid solution formulations. Pharmaceutical Research 21: 245- 253, 2004.
23. Khoo SM, Shackleford DM, Porter CJH, Edwards GA and Charman WN. Intestinal lymphatic transport of halofantrine occurs after oral administration of a unit-dose lipid-based formulation to fasted dogs. Pharmaceutical Research 20: 1460-1465, 2003.
24. Kossena GA, Boyd BJ, Porter CJ and Charman WN. Separation and characterization of the colloidal phases produced on digestion of common formulation lipids and assessment of their impact on the apparent solubility of selected poorly water-soluble drugs. Journal of Pharmaceutical Sciences 92: 634-648, 2003.
25. Kossena GA, Boyd BJ, Porter CJH and Charman WN. Separation and characterization of the colloidal phases produced on digestion of common formulation lipids and assessment of their drugs. Journal of Pharmaceutical Sciences 92: 634-648, 2003.
26. Kossena GA, Charman WN, Boyd BJ and Porter CIH. Influence of the intermediate digestion phases of common formulation lipids on the absorption of a poorly water-soluble drug. Journal of Pharmaceutical Sciences 94: 481-492, 2005.
27. Larsen, A., Jannin, V., and Mullertz, A. Pharmaceutical surfactants in biorelevant media: Impact on lipolysis and solubility of a Pharmaceutics Biopharmaceutics and Pharmaceutical Technology. 2006. Geneva, Switzerland. Ref Type: Conference Proceeding
28. Lowe ME. The triglyceride lipases of the pancreas. Journal of Lipid Research 43: 2007-2016, 2002.
29. Lowe ME. The triglyceride lipases of the pancreas. Journal of Lipid Research 43: 2007-2016, 2002.
30. MacGregor KJ, Embleton JK, Lacy JE, Perry EA, Solomon LJ, Seager H and Pouton CW. Influence of lipolysis on drug absorption from the gastro-intestinal tract. Advanced Drug Delivery Reviews 25: 33-46, 1997.
31. Mueller EA, Kovarik JM, Vanbree JB, Grevel J, Lucker PW and Kutz K. Influence of A Fat-Rich Meal on the Pharmacokinetics of A New Oral Formulation of Cyclosporine in A Crossover Comparison with the Market Formulations. Pharmaceutical Research 11: 151-155, 1994.
32. Nielsen FS, Gibault E, Ljusberg-Wahren H, Arleth L, Pedersen JS and Mullertz A. Characterization of prototype self-nanoemulsifying formulations of lipophilic compounds. J Pharm Sci 96: 876-892, 2007.
33. Odeberg JM, Kaufmann P, Kroon KG and Hoglund P. Lipid drug delivery and rational formulation design for lipophilic drugs with low oral bioavailability, applied to cyclosporine. European Journal of Pharmaceutical Sciences 20: 375-382, 2003.
34. Porter CJH and Charman WN. Intestinal lymphatic drug transport: an update. Advanced Drug Delivery Reviews 50: 61-80, 2001.
35. Porter CJH, Kaukonen AM, Boyd BJ, Edwards GA and Charman WN. Susceptibility to lipase-mediated digestion reduces the oral bioavailability of danazol after administration as a medium-chain lipid-based microemulsion formulation. Pharmaceutical Research 21: 1405-1412, 2004.
36. Porter CJH, Kaukonen AM, Taillardat-Bertschinger A, Boyd BJ, O'Connor JM, Edwards GA and Charman WN. Use of in vitro lipid digestion data to explain the in vivo performance of triglyceridebased oral lipid formulations of poorly water-soluble drugs: Studies with halofantrine. Journal of Pharmaceutical Sciences 93: 1110- 1121, 2004.
37. Pouton CW. Lipid formulations for oral administration of drugs: non-emulsifying, self-emulsifying and 'selfmicroemulsifying' drug delivery systems. Eur J Pharm Sci 11 Suppl 2: S93-S98, 2000.
38. Pouton CW. Formulation of poorly water-soluble drugs for oral administration: physicochemical and physiological issues and the lipid formulation classification system. Eur J Pharm Sci 29: 278-287, 2006.
39. Rigler MW, Honkanen RE and Patton JS. Visualization by freeze fracture, in vitro and in vivo, of the products of fat digestion. Journal of Lipid Research 27: 836-857, 1986.
40. SHANKLAN.W. Ionic Behavior of Fatty Acids Solubilized by Bile Salts. Journal of Colloid and Interface Science 34: 9-&, 1970.
41. Staggers JE, Hernell O, Stafford RJ and Carey MC. Physical- Chemical Behavior of Dietary and Biliary Lipids During Intestinal Digestion and Absorption .1. Phase-Behavior and Aggregation States of Model Lipid Systems Patterned After Aqueous Duodenal Contents of Healthy Adult Human-Beings. Biochemistry 29: 2028-2040, 1990.
42. van Tilbeurgh H, Bezzine S, Cambillau C, Verger R and Carriere F. Colipase: structure and interaction with pancreatic lipase. Biochimica et Biophysica Acta-Molecular and Cell Biology of Lipids 1441: 173-184, 1999.
43. Verger R, Moreau H, Gargouri Y, Laugier R, Bernadac A, Moulin A, Ferrato F, Rogalska E, Carriere F, Ransac S and Riviere C. Lipases of the Digestive-Tract - Biochemical and Physiological- Aspects. Biological Chemistry Hoppe-Seyler 370: 989-990, 1989.
44. Vonderscher J and Meinzer A. Rationale for the development of Sandimmune Neoral. Transplant Proc 26: 2925-2927, 1994.
45. Zangenberg NH, Mullertz A, Kristensen HG and Hovgaard L. A dynamic in vitro lipolysis model. I. Controlling the rate of lipolysis by continuous addition of calcium. Eur J Pharm Sci 14: 115-122, 2001.
46. Zangenberg NH, Mullertz A, Kristensen HG and Hovgaard L. A dynamic in vitro lipolysis model. I. Controlling the rate of lipolysis by continuous addition of calcium. Eur J Pharm Sci 14: 115-122, 2001.
47. Zangenberg NH, Mullertz A, Kristensen HG and Hovgaard L. A dynamic in vitro lipolysis model. II: Evaluation of the model. Eur J Pharm Sci 14: 237-244, 2001.